Clinical Trials
17 trialsNCT06589804 2026-05-22
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT05063552 2026-05-13
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT06835569 2026-05-06
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Alterome Therapeutics, Inc.
Phase 1 Recruiting
NCT07441681 2026-05-04
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
NRG Oncology
Phase 3 Not yet recruiting
NCT07411599 2026-04-23
Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT03258554 2026-02-06
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT00545545 2025-03-19
Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma
HiberCell, Inc.
Phase 1/2 Completed
NCT01855451 2022-11-18
HPVOropharynx
Trans Tasman Radiation Oncology Group
Phase 3 Unknown
NCT00468169 2019-10-09
EPIC
University of Chicago
Phase 2 Completed
NCT01063075 2019-09-26
A Study in Advanced Solid Tumors
Eli Lilly and Company
Phase 2 Completed
NCT01099358 2019-09-26
Study in Advanced Solid Tumors
Eli Lilly and Company
Phase 2 Completed
NCT01218048 2018-08-16
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
University of Pittsburgh
Phase 2 Completed
NCT00570674 2017-11-13
Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT02298595 2017-11-13
Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
University of Pittsburgh
Phase 1/2 Withdrawn
NCT01109524 2015-12-24
Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00894569 2009-05-14
PACET-CUP
Heidelberg University
Phase 2 Unknown
NCT00353717 2009-01-13
Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma
Hadassah Medical Organization
Phase 1/2 Unknown